These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Treatment of Paget's disease of bone (osteitis deformans) with sodium etidronate (EHDP). Rashid M; Khairi A; Johnston C Clin Orthop Relat Res; 1977; (127):94-105. PubMed ID: 410576 [No Abstract] [Full Text] [Related]
4. Effects of different regimens of sodium fluoride treatment for osteoporosis on the structure, remodeling and mineralization of bone. Balena R; Kleerekoper M; Foldes JA; Shih MS; Rao DS; Schober HC; Parfitt AM Osteoporos Int; 1998; 8(5):428-35. PubMed ID: 9850350 [TBL] [Abstract][Full Text] [Related]
5. Biochemical markers of bone turnover in Paget's disease. Russell RG; Beard DJ; Cameron EC; Douglas DL; Forrest AR; Guilland-Cumming D; Paterson AD; Poser J; Preston CJ; Milford-Ward A; Woodhead S; Kanis JA Metab Bone Dis Relat Res; 1981; 3(4-5):255-62. PubMed ID: 6220191 [TBL] [Abstract][Full Text] [Related]
6. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity. Alvarez L; Peris P; Pons F; Guañabens N; Herranz R; Monegal A; Bedini JL; Deulofeu R; Martínez de Osaba MJ; Muñoz-Gómez J; Ballesta AM Arthritis Rheum; 1997 Mar; 40(3):461-8. PubMed ID: 9082934 [TBL] [Abstract][Full Text] [Related]
7. Quantification of biochemical markers of bone turnover by kinetic measures of bone formation and resorption in young healthy females. Weaver CM; Peacock M; Martin BR; McCabe GP; Zhao J; Smith DL; Wastney ME J Bone Miner Res; 1997 Oct; 12(10):1714-20. PubMed ID: 9333133 [TBL] [Abstract][Full Text] [Related]
8. [Treatment of Paget's disease of bone with ethane-1 hydroxy-1, 1 diphosphonate at low dosage (author's transl)]. Alexandre C; Chapuy MC; Bressot C; Vignon E; Arlot M; Mathieu L; Edouard C; Johnston CC; Meunier PJ Nouv Presse Med; 1980 Nov; 9(45):3429-33. PubMed ID: 6777752 [TBL] [Abstract][Full Text] [Related]
9. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. Siris E; Weinstein RS; Altman R; Conte JM; Favus M; Lombardi A; Lyles K; McIlwain H; Murphy WA; Reda C; Rude R; Seton M; Tiegs R; Thompson D; Tucci JR; Yates AJ; Zimering M J Clin Endocrinol Metab; 1996 Mar; 81(3):961-7. PubMed ID: 8772558 [TBL] [Abstract][Full Text] [Related]
10. Diphosphonate treatment of Paget's disease of bone. A correlated metabolic, calcium kinetic and morphometric study. Guncaga J; Lauffenburger T; Lentner C; Dambacher MA; Haas HG; Fleisch H; Olah AJ Horm Metab Res; 1974 Jan; 6(1):62-9. PubMed ID: 4819289 [No Abstract] [Full Text] [Related]
11. Paget's disease of bone. Experience with a diphosphonate (disodium etidronate) in treatment. Smith R; Russell RG; Bishop MC; Woods CG; Bishop M Q J Med; 1973 Apr; 42(166):235-56. PubMed ID: 4206518 [No Abstract] [Full Text] [Related]
12. Quantitative evaluation of bone scintigraphy in the assessment of Paget's disease activity. Pons F; Alvarez L; Peris P; Guañabens N; Vidal-Sicart S; Monegal A; Pavía J; Ballesta AM; Muños-Gómez J; Herranz R Nucl Med Commun; 1999 Jun; 20(6):525-8. PubMed ID: 10451864 [TBL] [Abstract][Full Text] [Related]
13. The treatment of Paget's bone disease with sodium ethidronate. Fromm GA; Schajowicz F; Casco C; Ghiringhelli G; Mautalen CA Am J Med Sci; 1979; 277(1):29-37. PubMed ID: 106728 [TBL] [Abstract][Full Text] [Related]
14. [Treatment of 10 cases of symptomatic Paget's disease with etidronate (EHDP)]. Jung A; Mermillod B; Schenk R; Courvoisier B; Burkhardt P; Epiney J; Fleisch Schweiz Med Wochenschr; 1976 Nov; 106(48):1667-73. PubMed ID: 827810 [TBL] [Abstract][Full Text] [Related]
15. Are Biochemical Markers of Bone Turnover Representative of Bone Histomorphometry in 370 Postmenopausal Women? Chavassieux P; Portero-Muzy N; Roux JP; Garnero P; Chapurlat R J Clin Endocrinol Metab; 2015 Dec; 100(12):4662-8. PubMed ID: 26505821 [TBL] [Abstract][Full Text] [Related]
16. The effect of fluoride on 45Ca kinetics in Paget's disease. Lukert BP; Bolinger RE; Meek JC J Clin Endocrinol Metab; 1972 Sep; 35(3):387-91. PubMed ID: 5051361 [No Abstract] [Full Text] [Related]
17. Long term effects of dichloromethylene diphosphonate in Paget's disease of bone. Delmas PD; Chapuy MC; Vignon E; Charhon S; Briancon D; Alexandre C; Edouard C; Meunier PJ J Clin Endocrinol Metab; 1982 Apr; 54(4):837-44. PubMed ID: 6460781 [TBL] [Abstract][Full Text] [Related]
18. The assessment of bone formation and bone resorption in osteoporosis: a comparison between tetracycline-based iliac histomorphometry and whole body 85Sr kinetics. Reeve J; Arlot ME; Chavassieux PM; Edouard C; Green JR; Hesp R; Tellez M; Meunier PJ J Bone Miner Res; 1987 Dec; 2(6):479-89. PubMed ID: 3455632 [TBL] [Abstract][Full Text] [Related]
19. Impaired osteoblast function in osteoporosis: comparison between calcium balance and dynamic histomorphometry. Arlot M; Edouard C; Meunier PJ; Neer RM; Reeve J Br Med J (Clin Res Ed); 1984 Sep; 289(6444):517-20. PubMed ID: 6432170 [TBL] [Abstract][Full Text] [Related]
20. The clinical and metabolic effects of porcine calcitonin on Paget's disease of bone. Shai F; Baker RK; Wallach S J Clin Invest; 1971 Sep; 50(9):1927-40. PubMed ID: 4935444 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]